NATICK, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the appointment of Christopher B. Primiano as Vice President, General Counsel and Secretary.
Help employers find you! Check out all the jobs and post your resume.
